Salvador Ventura, new director of the Parc Taulí Research and Innovation Institute (I3PT)

CERCA system

Dr. Salvador Ventura Zamora has been appointed director of the Parc Taulí Research and Innovation Institute (I3PT)-CERCA by the Taulí of Trustees of the institution.

Ventura will assume the leadership of the I3PT from September 1, 2024.

He holds a degree in Biology from the University of Barcelona (UB), a master’s degree in Biochemistry and Molecular Biology from the Autonomous University of Barcelona (UAB) and a PhD in Biochemistry and Molecular Biology from the UAB.

“It is a privilege for me to assume the direction of the Parc Taulí Research and Innovation Institute. I am very grateful to the Taulí of Trustees for their trust and I hope to be able to contribute to the Institute’s growth and scientific excellence. I face this new stage with the desire to find solutions to the great challenges in health, working together with the excellent professionals of Parc Taulí”, declared the new director.

Ventura is ICREA Academy researcher and professor from the Department of Biochemistry and Molecular Biology at the Faculty of Biosciences of the UAB. His research career has developed mainly in the area of conformational diseases caused by protein misfolding. From 2017 to 2020, Ventura has been director of the Institute of Biotechnology and Biomedicine (IBB) “Vicent Villar i Palasí” of the UAB. In 2022 he received the Narcís Monturiol Medal to scientific and technological merit and has recently been elected member of the European Academy in recognition of his research work.

The challenges of the new direction

The new direction of the I3PT aims to continue driving the scientific and innovative excellence of the professionals of Parc Taulí, especially in the international arena, with an impact on improving the diagnosis and treatment of diseases. In this sense, one of the main challenges is to promote the two transversal areas of research – Data and Technological Innovation in Health and omics – so that collaborative projects can be carried out with research groups; the collection of resources to provide the Institute with the most advanced infrastructures and equipment; the promotion of activity related to clinical trials; the promotion of the recruitment and retention of talent; and collaboration with other sector institutions and technology companies.

Along these lines, during a visit to the I3PT, accompanied by the general director of the CSPT, Anna Aran, and the current director of the Institute, Lluís Blanch, Ventura explained:

“at a time of technological revolution and knowledge in biomedicine, the I3PT is ready and willing to lead this change. We aspire to consolidate ourselves as a leading institution in international health innovation, fostering a synergy of cutting-edge basic, clinical and translational research”

Dr Salvador Ventura


More news